🧬 Longevity
A Cholesterol Pill That Matches an Injection Just Got FDA Approval. Here’s What 30 Million Untreated Patients Cost Us.
Merck’s Lipfendra cuts LDL cholesterol by 60% in a once-daily tablet costing $315 a month, and the real story is the tens of thousands of heart attacks the injection barrier may have caused.
Twenty-seven million Americans have cholesterol that statins cannot bring under control. For a decade, a fix has existed: injectable PCSK9 inhibitors that slash LDL by roughly 60%, the single most powerful cholesterol-lowering tool ever demonstrated in large cardiovascular outcomes trials, drugs so effective that cardiologists began calling them the most important advance since statins themselves. Fewer than three million use them. Needles.
On July 16, the FDA approved Merck’s Lipfendra (enlicitide), the first oral PCSK9 inhibitor: a once-daily pill that achieves the same 56–60% LDL reduction as the injections at a list price of $315 per month, roughly 35% cheaper than Amgen’s Repatha and 42% below Novartis’s Leqvio, effectively removing the two barriers that kept tens of millions of eligible patients from ever starting treatment. But the timing stings. Tens of thousands of patients may have suffered preventable heart attacks while the needle stood between them and treatment.
The Trial Data
Merck’s phase III CORALreef program tested a 20 mg dose across two pivotal trials. CORALreef Lipids enrolled 2,912 adults and showed a 56% placebo-adjusted LDL-C reduction at 24 weeks. CORALreef HeFH showed 59% in familial hypercholesterolemia. Side effects tracked placebo closely, except for modestly higher rates of diarrhea (7% versus 2%) and dizziness (9% versus 4%), neither of which prompted significant trial discontinuation. A separate head-to-head trial demolished the other non-statin oral options: 78.2% of enlicitide patients achieved both a 50%-or-greater LDL reduction and an absolute level below 55 mg/dL, compared with 8.0% for ezetimibe, 2.0% for bempedoic acid, and 20.0% for both drugs combined.
Calculating What Needles Have Cost Us
Amgen’s landmark FOURIER trial in the New England Journal of Medicine randomized 27,564 patients to injectable evolocumab or placebo on top of statins. Over 2.2 years, the composite of cardiovascular death, heart attack, stroke, and revascularization dropped from 11.3% to 9.8%, an absolute risk reduction of 1.5 percentage points, yielding a number needed to treat of roughly 67.
About 3 million Americans take a PCSK9 inhibitor today, but adjusted for real-world adherence data showing only 48.9% are still taking the drug at six months, the effective annual NNT doubles to about 300, yielding roughly 10,000 major cardiovascular events prevented per year. Now consider the 27 million statin-inadequate Americans not on any PCSK9 therapy. Halving the annual absolute risk reduction to 0.34% for this blended-risk pool gives an NNT of roughly 294. If an oral pill recruited just five million of those 27 million into treatment at 70% adherence, the math produces approximately 11,900 additional major cardiovascular events prevented per year.
| Scenario | Patients | Adherence | Annual ARR | Events Prevented/Yr |
|---|---|---|---|---|
| Current injectable users | 3.0M | ~49% | 0.68% | ~10,000 |
| +5M new oral patients (blended risk) | 5.0M | ~70% | 0.34% | ~11,900 |
| Combined total | 8.0M | ~21,900 |
Between the 10,000 events prevented today and a theoretical maximum of ~102,000 (all 30 million at full adherence) lies a hidden cardiovascular toll. Cardiologists estimate the injection barrier accounts for 30–50% of the treatment gap, which works out to between 25,000 and 46,000 additional preventable cardiovascular events per year. A pill existed in theory. Nobody built one fast enough.
Strongest Counterargument: No Outcomes Data Yet
Everything in this calculation depends on one unproven assumption: that Lipfendra’s 60% LDL reduction will translate into fewer heart attacks at rates comparable to the injectable PCSK9 inhibitors tested in FOURIER, a trial that measured a composite endpoint over just 2.2 years and was stopped early for benefit, precluding definitive mortality analysis. LDL-C is a surrogate endpoint, an intermediate marker regulators accept because the causal chain from LDL to cardiovascular events is well-established, but one that has occasionally failed to predict outcomes in other drug classes. Merck has a cardiovascular outcomes trial underway; it will not report until 2029. Worth noting: a reanalysis of FOURIER in BMJ Open found total mortality numerically higher in the evolocumab group, though not statistically significantly. Until Lipfendra generates its own long-term data, this entire calculation is inference, not proof.
A second wrinkle: oral adherence is not an automatic upgrade. Statins are daily pills, and their 12-month adherence rates hover around 50%, not far above what injectables manage, because pills carry their own compliance friction. Lipfendra adds a wrinkle: empty stomach, 30-minute fast. If real-world adherence lands at 55% rather than 70%, the projected gains shrink from 11,900 to roughly 9,400 additional events prevented.
Limitations
This analysis extrapolates cardiovascular outcomes from injectable PCSK9 inhibitor trials to an oral drug that has proven only LDL reduction, not event prevention. Patient population modeling uses US-centric data; treatment gaps, pricing, and access dynamics differ substantially in other markets. Adherence assumptions for the oral format (70%) are based on analogy to other chronic-disease pills, not on measured Lipfendra adherence. Injection-barrier estimates (30–50% of the treatment gap) vary by practice setting and survey methodology. Cost comparisons use list prices; net prices after rebates may narrow or widen the gap.
Bottom Line
Lipfendra is a real engineering achievement: a pill that does what a biologic injection does, at a lower price, with no serious safety signals so far. Our estimate suggests the oral format could prevent roughly 12,000 additional heart attacks and strokes per year in the US alone, if even a fraction of the undertreated population gains access. That number rests on extrapolated outcomes data, and Merck’s cardiovascular outcomes trial due in 2029 will settle it. Merck is not acting out of charity: Keytruda faces patent expiration in 2028, and Wall Street puts Lipfendra’s peak sales at roughly $5 billion, filling only 16% of the revenue crater. Four PCSK9 delivery formats will soon compete for the same patients: biweekly injection, monthly injection, twice-yearly injection, and daily pill. If you have already maximized statin therapy and your LDL remains above target, Lipfendra is worth discussing with your cardiologist when it launches in the coming weeks.